Jean-Marie Eveillard (Trades, Portfolio) is Chief Investment Officer of the Arnhold and S. Bleichroeder Advisers, LLC Global Value Team and Portfolio Manager of First Eagle Global, Overseas, Gold, U.S. Value and Overseas Variable Funds.
His portfolio has a total value of $41,155 Mil and is composed of 342 stocks. According to GuruFocus Real Time Picks, on April 29, the investor increased his stake in Arqule Inc (ARQL) for the 11th time since the first buy in late Q1 of 2010.
With this new buy, Eveillard increased his stake by 96.18% with an impact of 0.02% to his portfolio and he is now holding 8,719,968 shares at an average price of $3.75/share.
The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIPTM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing.
ARQL has a profitability & growth rated 1/10 with deep negative returns (ROE -47.12%, ROA -29.13%, ROC -3769.80%) that are ranked higher than 57% of other companies in the Global Biotechnology industry.
Even financial strength is rated 1/10 with cash to debt rated as “No Debt” at best levels compared to company’s history and company’s industry.
The company has negative growth over the last 5 years with a revenue declining by 22.80%, EBITDA by 14.30% and EPS by 15.20%
The price over the last 12 months rose by 33% and is now +100.96% from its 52 Weeks Low and -16.40% from its 52 Weeks High.
Paolo Pucci, CEO of the company, talking about the future, said:
...in 2015 we have one more very significant cost saving activity planned. We believe the premises where we have been since I'm here at ArQule and this we'll move to an office which is least not far from where we're and on an annualized base move from the current side to the next office will reduce our operating expenses by approximately 5 million 4.4 on an annualized basis, meaning you won't be realizing all this year because we moving next year, but next year once you take the full year we will have reduced significantly yet again our core operating expenses.
In summary we look to a very promising 2015 and with that I'd like to pass the mic to Rob and he will walk you through the financials.
The company will report the first quarter 2015 financial results on May 6, 2015
